UBS Group AG Sells 1,660,285 Shares of Maravai LifeSciences Holdings, Inc. $MRVI

UBS Group AG decreased its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 69.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 738,927 shares of the company’s stock after selling 1,660,285 shares during the quarter. UBS Group AG owned approximately 0.29% of Maravai LifeSciences worth $2,402,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Jane Street Group LLC grew its stake in shares of Maravai LifeSciences by 1,463.1% during the 1st quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock valued at $841,000 after acquiring an additional 356,067 shares during the period. Creative Planning lifted its holdings in Maravai LifeSciences by 49.6% during the second quarter. Creative Planning now owns 116,031 shares of the company’s stock valued at $280,000 after purchasing an additional 38,450 shares in the last quarter. Rhumbline Advisers lifted its holdings in Maravai LifeSciences by 20.3% during the second quarter. Rhumbline Advisers now owns 195,272 shares of the company’s stock valued at $471,000 after purchasing an additional 32,940 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of Maravai LifeSciences in the second quarter worth approximately $36,000. Finally, Invesco Ltd. increased its stake in shares of Maravai LifeSciences by 16.8% in the second quarter. Invesco Ltd. now owns 282,192 shares of the company’s stock worth $680,000 after purchasing an additional 40,495 shares in the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Down 0.5%

Shares of MRVI stock opened at $4.38 on Wednesday. The company’s fifty day simple moving average is $3.57 and its two-hundred day simple moving average is $3.50. Maravai LifeSciences Holdings, Inc. has a 52 week low of $1.99 and a 52 week high of $4.99. The stock has a market cap of $1.13 billion, a P/E ratio of -6.17 and a beta of 0.62. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The firm had revenue of $65.84 million during the quarter, compared to analyst estimates of $53.00 million. Analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on MRVI shares. Weiss Ratings downgraded shares of Maravai LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a report on Friday, May 8th. Wells Fargo & Company raised their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.